SciELO - Scientific Electronic Library Online

vol.55 número1Marcadores de daño muscular en deportistas jóvenes de la Federación Deportiva de la Provincia Azuay, EcuadorDeterminación de anticuerpos anti-dsDNA: evaluación del desempeño de un inmunoensayo quimioluminiscente y correlación con el método de inmunofluorescencia indirecta índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados




  • Não possue artigos citadosCitado por SciELO

Links relacionados


Acta bioquímica clínica latinoamericana

versão impressa ISSN 0325-2957versão On-line ISSN 1851-6114


CONIGLIO, Raúl Ignacio. Apolipoproteína B: sus ventajas en el manejo del riesgo cardiovascular aterosclerótico. Acta bioquím. clín. latinoam. [online]. 2021, vol.55, n.1, pp.11-20. ISSN 0325-2957.

The determination of apolipoprotein B (Apo B) in the evaluation and treatment of atherosclerotic cardiovascular disease (ACVD) is analyzed, referring to three aspects: a) marker of atherogenic risk; b) advantages over lipids; c) utility in the biochemical laboratory. Apo B participates in atherogenesis. Atherogenic lipoprotein particles are usually evaluated for their cholesterol content, but their mass per particle is highly variable. However, each particle has an Apo B molecule so it is an estimator of its number and a marker of risk. Apo B plays a causal role and explains better than LDL cholesterol (LDL-C) the etiological relationship with the disease; it has a greater discriminating capacity than lipids, family aggregation and it is a better parameter for the management of treatment in the presence of LDL-C<70 mg/dL, moderate hypertriglyceridemia, metabolic syndrome, obesity, and diabetes. It can be determined without prior fasting with traceability to a reference standard, comparability and harmony of results between laboratories and lower analytical error than non-HDL cholesterol. LDL-C remains the primary endpoint for the evaluation and treatment of atherogenic risk. By consensus, cut-off values for Apo B have been reported according to ACVD risk categories and its use was recommended when it is possible to determine it. Apo B is an excellent marker of atherogenic risk, it has greater accuracy and precision than lipids and its inclusion in the management of specific clinical cases contributes to improving the quality of treatment.

Palavras-chave : Apolipoprotein B; Atherosclerotic cardiovascular disease; Cardiovascular risk; LDL-cholesterol; Non-HDL cholesterol.

        · resumo em Português | Espanhol     · texto em Espanhol     · Espanhol ( pdf )